CL2022003578A1 - Fusiones heterodiméricas de relaxina y usos de las mismas - Google Patents

Fusiones heterodiméricas de relaxina y usos de las mismas

Info

Publication number
CL2022003578A1
CL2022003578A1 CL2022003578A CL2022003578A CL2022003578A1 CL 2022003578 A1 CL2022003578 A1 CL 2022003578A1 CL 2022003578 A CL2022003578 A CL 2022003578A CL 2022003578 A CL2022003578 A CL 2022003578A CL 2022003578 A1 CL2022003578 A1 CL 2022003578A1
Authority
CL
Chile
Prior art keywords
relaxin
heterodimeric
treatment
fusions
fusion polypeptides
Prior art date
Application number
CL2022003578A
Other languages
English (en)
Inventor
Sermadiras Isabelle
Anna Papworth Monika
Christiane Paterson Judy
Marie Martin Esther
Ke Peng
Original Assignee
Medimmune Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Ltd filed Critical Medimmune Ltd
Publication of CL2022003578A1 publication Critical patent/CL2022003578A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/64—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/2221—Relaxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K19/00—Hybrid peptides, i.e. peptides covalently bound to nucleic acids, or non-covalently bound protein-protein complexes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A61K47/6811—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates the drug being a protein or peptide, e.g. transferrin or bleomycin
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/30—Non-immunoglobulin-derived peptide or protein having an immunoglobulin constant or Fc region, or a fragment thereof, attached thereto
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/31—Fusion polypeptide fusions, other than Fc, for prolonged plasma life, e.g. albumin

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Cardiology (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Endocrinology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Biotechnology (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Biomedical Technology (AREA)
  • Toxicology (AREA)
  • Hospice & Palliative Care (AREA)
  • Immunology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La presente invención se refiere a polipéptidos de fusión heterodiméricos de Relaxina, en particular, a polipéptidos de fusión heterodiméricos de Relaxina 2 y a usos de los mismos. Por tanto, la invención proporciona polipéptidos de fusión de Relaxina, moléculas de ácido nucleico, vectores, células hospedadoras, composiciones farmacéuticas y kits que comprenden los mismos y usos de los mismos, incluyendo métodos de tratamiento. Los polipéptidos y las composiciones de la invención pueden ser útiles, en particular, en el tratamiento de enfermedades cardiovasculares, por ejemplo, para el tratamiento de la insuficiencia cardíaca.
CL2022003578A 2020-06-17 2022-12-15 Fusiones heterodiméricas de relaxina y usos de las mismas CL2022003578A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US202063040250P 2020-06-17 2020-06-17

Publications (1)

Publication Number Publication Date
CL2022003578A1 true CL2022003578A1 (es) 2023-06-09

Family

ID=76584509

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2022003578A CL2022003578A1 (es) 2020-06-17 2022-12-15 Fusiones heterodiméricas de relaxina y usos de las mismas

Country Status (17)

Country Link
US (2) US11795205B2 (es)
EP (1) EP4168434A1 (es)
JP (1) JP2023530335A (es)
KR (1) KR20230024994A (es)
CN (1) CN115916813A (es)
AR (1) AR125007A1 (es)
AU (2) AU2021290997C1 (es)
BR (1) BR112022025019A2 (es)
CA (1) CA3186143A1 (es)
CL (1) CL2022003578A1 (es)
CO (1) CO2023000038A2 (es)
CR (1) CR20230015A (es)
EC (1) ECSP23002960A (es)
IL (1) IL298786A (es)
MX (1) MX2022016340A (es)
TW (1) TW202214673A (es)
WO (1) WO2021255127A1 (es)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT1355919E (pt) 2000-12-12 2011-03-02 Medimmune Llc Moléculas com semivida longa, composições que as contêm e suas utilizações
US8389475B2 (en) * 2009-08-10 2013-03-05 The Board Of Trustees Of The Leland Stanford Junior University Relaxin analogs
CN103429620B (zh) * 2010-11-05 2018-03-06 酵活有限公司 在Fc结构域中具有突变的稳定异源二聚的抗体设计
JP2014522641A (ja) * 2011-07-01 2014-09-08 バイエル・インテレクチュアル・プロパティ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング リラキシン融合ポリペプチドおよびその使用
AR094147A1 (es) * 2012-12-27 2015-07-15 Bayer Pharma Aktiengellschaft Polipeptidos de fusion con actividad de relaxina y sus usos
CA2946503C (en) 2014-05-28 2022-11-22 Zymeworks Inc. Modified antigen binding polypeptide constructs and uses thereof
WO2018138170A1 (en) 2017-01-25 2018-08-02 Medimmune, Llc Relaxin fusion polypeptides and uses thereof

Also Published As

Publication number Publication date
CA3186143A1 (en) 2021-12-23
AU2021290997B2 (en) 2023-10-12
AU2024200074A1 (en) 2024-01-25
WO2021255127A1 (en) 2021-12-23
EP4168434A1 (en) 2023-04-26
AR125007A1 (es) 2023-05-31
TW202214673A (zh) 2022-04-16
KR20230024994A (ko) 2023-02-21
JP2023530335A (ja) 2023-07-14
BR112022025019A2 (pt) 2022-12-27
US20240025958A1 (en) 2024-01-25
US11795205B2 (en) 2023-10-24
US20220017591A1 (en) 2022-01-20
CO2023000038A2 (es) 2023-01-16
IL298786A (en) 2023-02-01
CN115916813A (zh) 2023-04-04
MX2022016340A (es) 2023-01-24
AU2021290997A1 (en) 2023-02-09
CR20230015A (es) 2023-02-17
AU2021290997C1 (en) 2024-01-04
ECSP23002960A (es) 2023-03-31

Similar Documents

Publication Publication Date Title
CL2022000300A1 (es) Muteínas de interleucina 21 y sus usos para tratar tumores sólidos (divisional de la solicitud no. 202000252)
ECSP088262A (es) Proteínas de fusión de albúmina
BR112018072946A2 (pt) proteínas de fusão a gdf15 e usos das mesmas
CL2011003121A1 (es) Proteína de fusión que comprende una secuencia de hormona de crecimiento (gh), ligada a un polipéptido recombinante extendido (xten) que comprende al menos 200 aminoácidos, carece de epítopes de células t y los residuos g, a, s, t, e y p suman más del 90%; ácido nucleico, vector y célula; método de producción; composición farmacéutica y uso.
ECSP20025070A (es) Proteínas trispecificas y métodos de uso
BRPI0609797B8 (pt) nanocorpos melhorados para o tratamento de desordens mediadas por agregação
ECSP099401A (es) Polipeptidos heterologos il-17a/f y usos terapeuticos de los mismos
AR076541A1 (es) Mutantes de fgf21 y usos del mismo
BR112019009106A2 (pt) método para aumentar os níveis de secreção sem afetar as funções biológicas de il-2 de humano recombinante e suas proteínas mutantes derivadas, proteínas obtidas, e, usos do método e das proteínas obtidas
BR112018077375A2 (pt) kits, moléculas de anticorpo biespecífico trivalente, composição farmacêutica, vetor de expressão, célula hospedeira e método para a produção de uma molécula de anticorpo biespecífico trivalente
AR030236A1 (es) Moléculas similares a il-17 y usos de las mismas
BR112012006501A8 (pt) Polipeptídios e usos dos mesmos
BR112022016550A2 (pt) Proteínas de ligação a flt3 e métodos de uso
EA201990900A1 (ru) Стабильный при комнатной температуре лиофилизированный белок
AR013528A1 (es) PROTEíNA-2 QUIMIOTÁCTICA MONOCíTICA (MCP-2) HUMANA AMINO TERMINALMENTE TRUNCADA, MOLÉCULA DE ADN QUE LA CODIFICA, VECTOR DE EXPRESIoN Y CÉLULA HUÉSPED CORRESPONDIENTES, PROCESO RECOMBINANTE PARA PREPARAR DICHAS PROTEíNAS, USO DE DICHAS PROTEíNAS PARA LA FABRICACIoN DE UN MEDICAMENTO uTIL PARA LA TER
BR112022027096A2 (pt) Composições e métodos relacionados a agentes terapêuticos ativáveis
CO2020000369A2 (es) Polipéptidos que se unen al componente del complemento c5 o albumina sérica y proteínas de fusión de los mismos
BR112022019609A2 (pt) Células geneticamente modificadas enriquecidas com mitocôndrias e usos das mesmas
CO2021005083A2 (es) Distrofinas miniaturizadas y usos de las mismas
Wintrode et al. Solution structure and dynamics of a heat shock protein assembly probed by hydrogen exchange and mass spectrometry
Palasuberniam et al. Snake venom proteomics of samar cobra (Naja samarensis) from the southern Philippines: Short alpha-neurotoxins as the dominant lethal component weakly cross-neutralized by the philippine cobra antivenom
CO2023003453A2 (es) Proteínas de fusión inmunogénicas de coronavirus y métodos relacionados
CR20170507A (es) Fusiones de variante iii del receptor de factor de crecimiento epidérmico-mesotelina y métodos para usar los mismos.
CL2022003578A1 (es) Fusiones heterodiméricas de relaxina y usos de las mismas
CO2023017358A2 (es) Formulaciones de proteínas quiméricas del factor viii y usos de las mismas